Published online Jul 15, 2026. doi: 10.4251/wjgo.118787
Revised: February 11, 2026
Accepted: March 27, 2026
Published online: July 15, 2026
Processing time: 183 Days and 10 Hours
Gastric cancer develops through a sequence of atrophy, metaplasia, and dysplasia. Spasmolytic polypeptide-expressing metaplasia (SPEM) is a pivotal precancerous lesion associated with inflammation and noncoding RNA dysregulation. In traditional Chinese medicine (TCM), these pathological changes overlap with spleen-stomach deficiency syndrome (SSDS). Yiwei Xiaoyu granules (YWXY), a classical TCM formula, have demonstrated clinical benefit in chronic atrophic gastritis, yet their mechanistic actions in SPEM combined with SSDS remain unclear.
To investigate the protective effects and mechanisms of YWXY in a tamoxifen-induced SPEM and SSDS composite model.
A mouse model of tamoxifen-induced SPEM, with or without SSDS, was estab
YWXY exhibited time-dependent modulation of IL-1β, normalizing its expression at day 15 and suppressing persistent elevation at day 30. TNF-α overexpression in SPEM was significantly reduced by YWXY at both time points. Cdr1as downregulation in pathological groups was partially reversed by YWXY, while miR-7a-5p sup
YWXY alleviates gastric mucosal injury in combined SPEM and SSDS by regulating IL-1β and TNF-α, restoring the miR-7a-5p/Cdr1as axis, and suppressing WFDC2 expression.
Core Tip: Spasmolytic polypeptide-expressing metaplasia (SPEM) represents a key precancerous stage of gastric carcinogenesis and frequently coexists with spleen-stomach deficiency syndrome (SSDS) in clinical practice. Using a combined tamoxifen-induced SPEM and SSDS mouse model, we demonstrate that Yiwei Xiaoyu granules exert sustained protective effects on gastric mucosa. Yiwei Xiaoyu granules bidirectionally regulates inflammatory cytokines, restores the miR-7a-5p/Cdr1as axis, and suppresses WFDC2 induction, thereby linking syndrome-based intervention with molecular mechanisms of gastric precancerous lesions.